Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2 positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone

Conclusion:
PTEN was neither a significant prognostic nor predictive factor. PIK3CA mutations were an adverse prognostic factor for survival but not predictive for lapatinib benefit.Trial registrationClinicalTrials.gov NCT00281658 (registered 23 January 2006)

Source: Breast Cancer Research - July 24, 2014 Category: Cancer & Oncology Authors: Binghe XuZhongzhen GuanZhenzhou ShenZhongshen TongZefei JiangJunlan YangMichelle DeSilvioMark RussoMeggan LeighCatherine Ellis Source Type: research